, Tracking Stock Market Picks
Enter Symbol:
BioLineRx, Ltd. (BLRX) [hlAlert]

down 49.81 %

BioLineRx, Ltd. (BLRX) rated Buy with price target $7 by Aegis Capital

Posted on: Wednesday,  Mar 20, 2013  11:25 AM ET by Aegis Capital

Aegis Capital rated Buy BioLineRx, Ltd. (NASDAQ: BLRX) on 03/20/2013. Previously Aegis Capital rated Buy BioLineRx, Ltd. (NASDAQ: BLRX) on 10/02/2012.,
when the stock price was $2.71. Since then, BioLineRx, Ltd. has lost 49.82% as of 09/24/2015's recent price of $1.36.
If you would have followed the previous Aegis Capital's recommendation on BLRX, you would have lost 49.81% of your investment in 1087 days.

BioLineRx, Ltd. operates as a clinical-stage biopharmaceutical development company worldwide. Its clinical therapeutic candidates under development include BL-1020, a Phase IIb completed product for the treatment of schizophrenia; BL-1040, a Phase I/II clinical trial completed medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients; and BL-5010, a novel formulation under Phase I/II clinical trial for non surgical removal of skin lesions. The company?s product pipeline under pre-clinical stage of development includes BL-1021 for neuropathic pain; BL-2030 for autoimmune diseases; BL-4010 for cancer tumors; BL-4040 for acute kidney failure; BL-5030 for thromboembolic diseases; BL-5040 for inflammatory diseases and pathological weight loss; BL-6010 for type II diabetes; BL-6020 for cancer cachexia; and BL-6030 for bacterial biofilm. It also operates a biotechnology incubator to evaluate and develop pre-clinical therapeutic candidates. The company was founded in 2003 and is based in Jerusalem, Israel.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/20/2013 11:25 AM Buy
1.85 7.00
as of 12/13/2013
1 Week down  -1.54 %
1 Month up  0.39 %
3 Months up  18.60 %
1 YTD up  0.79 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/2/2012 8:25 AM Buy
2.71 11.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy